Olmat Tablets (Olmesartan Medoxomil )

• Composition :
  Each tablet contains Olmesartan medoxomil 20mg / 40mg
• Indications :
  It is used for the treatment of hypertension.
• Pharmacodynamics :
  Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. Angiotensin II is the principal pressor agent of the renin-angiotensin system, which leads to vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle.
• Dosage and administration :
  Adults: The usual recommended starting dose is 20 mg once daily. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of may be increased to 40 mg. Pediatric hypertension (6 to 16 years of age):For children who can swallow tablets, the usual recommended starting dose of olmesartan is 10 mg once daily for patients who weigh 20 to <35 kg, or 20mg once daily for patients who weigh >35 kg. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of olmesartan may be increased to a maximum of 20mg once daily for patients who weigh <35 kg or 40mg once daily for patients who weigh ≥ 35kg.
• Contraindications :
  Contraindicated in patients with known hypersensitivity to olmesartan ingredients or any other component of this product.
• Precautions and warnings :
  Observe for signs and symptoms of hypotensionin patients with an activated renin-angiotensin aldosterone system. Monitor for worsening renal function in patients with renal impairment.
• Use in pregnancy, lactation & pediatrics :
  Fetal toxicity Pregnancy Category D: Avoid use in pregnancy. It is not known whether olmesartan is excreted in human milk. Because of the potential for adverse effects on the nursing infant, hence choose to discontinue nursing or the drug. Olmesartan has not been shown to be effective for hypertension in children< 6 years of age. Children <1 year of age must not receive olmesartan for hypertension.
• Drug interactions :
  NSAIDs may lead to increased risk of renal impairment and loss of antihypertensive effect.
• Adverse reactions :
  The most common adverse reactionis dizziness.
• Therapy Area :
  Anti-Hypertensives